



CareSource considers Orilissa (elagolix) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
11/20/2018	New policy for Orilissa created.
10/23/2020	Removed requirement of negative pregnancy test or sterilization of partner (changed to no current pregnancy or plan to become pregnant); removed obstetrician as an option for prescriber.
08/23/2022	Annual review. Transferred to new template. Updated references.

References:

1. Orilissa [package insert]. North Chicago, IL: AbbVie Inc.; February 2021.
2. Taylor HS, Giudice LC, Lessey BA, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. *N Engl J Med* 2017;377:28-40
3. Schrager S, Falleroni J, Edgoose J. Evaluation and treatment of endometriosis. *Am Fam Physician*. 2013 Jan 3.